Related Experiment Videos
BMT: Bone Marrow Transplant Associated Thrombotic Microangiopathy
ALESSANDRO Busca1, CORNELIO Uderzo
1Department of Pediatrics, University of Turin, Italy.
Abstract:
Thrombotic microangiopathy is a severe microvascular disorder which may occur in up to 70% of patients undergoing bone marrow transplant. Clinically the term thrombotic microangiopathy encompasses a wide spectrum of syndromes, most importantly the thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Thrombotic microangiopathy is characterized by the presence of thrombocytopenia, microangiopathic hemolytic anemia, renal impairment, neurological disturbances and multiorgan failure. Several causative agents have been advocated as triggering factors for bone marrow transplant associated thrombotic microangiopathy, including cyclosporine, FK506, the use of total body irradiation, infections and the presence of severe graft-versus-host disease. Plasma exchange represents the standard treatment for patients who develop TTP/HUS after bone marrow transplant, however, the mortality rate still remains high despite aggressive therapy.
Insights
Thrombotic microangiopathy, a severe disorder affecting blood vessels, occurs in up to 70% of bone marrow transplant patients. Despite plasma exchange treatment for thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), mortality rates remain high.
Area of Science:
- Hematology
- Transplantation Medicine
- Vascular Biology
Background:
- Thrombotic microangiopathy (TMA) is a serious complication following bone marrow transplant (BMT), affecting up to 70% of patients.
- TMA encompasses syndromes like thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS), characterized by low platelets, anemia, and organ damage.
- Potential triggers for BMT-associated TMA include immunosuppressants (cyclosporine, FK506), radiation, infections, and graft-versus-host disease.
Purpose of the Study:
- To review the characteristics and management of thrombotic microangiopathy in bone marrow transplant recipients.
- To highlight the challenges in treating TTP/HUS post-BMT and the persistent high mortality rates.
Main Methods:
- Literature review of thrombotic microangiopathy in the context of bone marrow transplantation.
- Analysis of clinical presentation, causative agents, and treatment outcomes for TTP/HUS post-BMT.
Main Results:
- Thrombotic microangiopathy presents with thrombocytopenia, hemolytic anemia, renal impairment, neurological issues, and multiorgan failure.
- Despite plasma exchange being the standard therapy for TTP/HUS after BMT, high mortality persists.
Conclusions:
- Bone marrow transplant-associated thrombotic microangiopathy is a critical condition with significant morbidity and mortality.
- Further research into novel therapeutic strategies is essential to improve outcomes for TTP/HUS patients post-BMT.